title: SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988-1994.
abstract: OBJECTIVE
  1998 Surveillance, Epidemiology, and End Results (SEER) data estimate an 83.1% 5-year survival rate for corpus uteri adenocarcinoma FIGO stage II. The SEER data were evaluated to determine whether primary treatment differences using simple hysterectomy or radical hysterectomy, with or without radiation, altered disease survival.
  
  
  METHODS
  SEER incidence data for FIGO II uterine corpus cancer of adenocarcinoma histology from 1988 to 1994 were stratified by hysterectomy type (simple versus radical) and whether radiation was given. Survival rates were calculated using a relative survival method and are expressed as percentages. Statistical analysis was done using a Z test.
  
  
  RESULTS
  The 5-year cumulative survival rate for patients with stage II uterine corpus adenocarcinoma who received surgery alone as primary therapy was 84.36% with simple hysterectomy and 92.96% with radical hysterectomy (P<0.05). Survival for patients who received combination radiation and surgery as primary therapy was 82.77% with simple hysterectomy and 88.02% with radical hysterectomy (P<0.05). Pelvic and para-aortic nodes were negative. There was no significant survival difference for radiation versus no radiation in either surgical group.
  
  
  CONCLUSIONS
  Radical hysterectomy is associated with better survival when compared to simple hysterectomy for FIGO II corpus uteri adenocarcinoma.
authors.affiliation: Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, 20892, USA.
authors.forename: T L
authors.initials: TL
authors.lastname: Cornelison
authors.forename: E L
authors.initials: EL
authors.lastname: Trimble
authors.forename: C L
authors.initials: CL
authors.lastname: Kosary
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D009367:Neoplasm Staging; D018426:SEER Program; D015996:Survival Rate; D014594:Uterine Neoplasms / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*